The V590 vaccine was developed on Merck’s recombinant vesicular stomatitis virus (rVSV) platform that was previously used to develop its Ebola Zaire virus vaccine, ERVEBO®[A226818, L30573, L30578]. By teaming up with IAVI, Merk developed a vaccine that does n…